AUSTIN, Texas, Sept. 1, 2020 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition") today announced that its Chief
Executive Officer, Cameron Reynolds,
and its Executive Vice President, Investor Relations, Scott Powell, are scheduled to present at five
conferences in September 2020.
During the conferences, Mr. Reynolds and Dr. Powell will outline
Volition's business, clinical, regulatory and operational
milestones, as well as the Company's recently announced quarterly
financial results.
Details of the conference presentations (all virtual) are as
follows:
Conference:
LD Micro 500 Virtual Conference
Presentation Date/Time: Tuesday,
September 1, 2020, 9:00 am EDT
Registration
Link: https://ld500.ldmicro.com/
Conference: GCFF
Virtual Conference – Investing in Innovation
Presentation Date/Time: Thursday, September 10, 2020, 12:00 pm EDT
Registration
Link: https://nai500.com/events/gcff-2020-investing-in-innovation
Conference: Cantor
Virtual Global Healthcare Conference
Presentation Date/Time:
Tuesday, September 15,
2020, 8:00 am EDT
Registration
Link: https://cantor-fitzgerald-global-healthcare-conference.events.issuerdirect.com/signup
Conference: Life
Sciences Investor Forum
Presentation Date/Time:
Thursday, September 17, 2020,
10:00 am EDT
Registration
Link: https://bit.ly/30GjErk
Conference:
Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit
Presentation Date/Time:
Monday, September 21, 2020,
10:50 am EDT
Registration
Link: https://www.oppenheimer.com/events/2020/healthcare-fall-
summit.aspx
Participants joining any of the above-referenced conferences who
would like to schedule a virtual 1-on-1 meeting with Volition
management may do so by registering at the links above, or by
contacting Scott Powell, Executive Vice President of Investor
Relations, at investorrelations@volition.com.
About Volition
Volition is a multi-national epigenetics company developing
simple, easy to use, cost effective blood tests to help diagnose a
range of cancers and other diseases. Early diagnosis has the
potential to not only prolong the life of patients, but also to
improve their quality of life. The tests are based on the science
of NucleosomicsTM, which is the practice of identifying
and measuring nucleosomes in the bloodstream or other bodily fluid
- an indication that disease is present. Volition is primarily
focused on human diagnostics but also has a subsidiary focused on
animal diagnostics.
Volition's research and development activities are centered in
Belgium, with additional offices
in Texas, London and Singapore, as the company focuses on bringing
its diagnostic products to market.
NucleosomicsTM is a trademark and/or service mark of
VolitionRx Limited and its subsidiaries.
For more information about Volition, visit Volition's website
volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
|
View original
content:http://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-conferences-in-september-2020-301121771.html
SOURCE VolitionRx Ltd